Your browser doesn't support javascript.
loading
[Relevant thoughts on development of traditional Chinese medicine industry in new era].
Huang, Ju; Li, Geng; Zhang, Xiao-Xiao; Ma, Yong; Zhan, Zhi-Lai; Yuan, Wei-An; Qu, Li-Ping; Huang, Shi-Yao; Li, Bo; Yan, Bo-Hua; Li, Wen-Yuan; Liu, Li; Wang, Zhi-Lei; Feng, Yi; Zhang, Lei; Tang, Jian-Yuan.
Afiliación
  • Huang J; Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610032, China.
  • Li G; Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, Peking Union Medical College Beijing 100193, China.
  • Zhang XX; China Association of Chinese Medicine Beijing 100029, China.
  • Ma Y; School of Chinese Medicine·School of Integrated Chinese and Western Medicine,Nanjing University of Chinese Medicine Nanjing 210023, China.
  • Zhan ZL; National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China.
  • Yuan WA; Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine Shanghai 201203, China.
  • Qu LP; State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine Chengdu 610032, China.
  • Huang SY; Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610032, China.
  • Li B; Beijing Hospital of Traditional Chinese Medicine,Capital Medical University/Beijing Institute of Chinese Medicine/Beijing Evidence-based Chinese Medicine Center Beijing 100010, China.
  • Yan BH; Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610032, China.
  • Li WY; Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610032, China.
  • Liu L; Shanghai Pharmaceuticals Holding Co., Ltd. Shanghai 200020, China.
  • Wang ZL; Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610032, China.
  • Feng Y; Shanghai University of Traditional Chinese Medicine Shanghai 201203, China.
  • Zhang L; Shanghai University of Traditional Chinese Medicine Shanghai 201203, China.
  • Tang JY; Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610032, China.
Zhongguo Zhong Yao Za Zhi ; 47(17): 4799-4813, 2022 Sep.
Article en Zh | MEDLINE | ID: mdl-36164887
Since the 18th National Congress of the Communist Party of China(CPC), the CPC and the government have highligh-ted the development of traditional Chinese Medicine(TCM) and issued a series of policies, such as the Plan for Protection and Deve-lopment of Chinese Medicinal Materials(2015-2020) forwarded by the General Office of the State Council in 2015, the Plan for Healthy Development of Traditional Chinese Medicine(2015-2020) released by the General Office of the State Council in the same year, the Healthy China 2030 Plan published by the CPC Central Committee and the State Council in 2016, the Law of the People's Republic of China on Traditional Chinese Medicine which took effect on July 2017, On the Preservation and Innovative Development of Traditional Chinese Medicine promulgated by CPC Central Committee and the State Council in 2019, and Plan for the Development of Traditional Chinese Medicine during the 14th Five-Year Plan Period of China released by the General Office of the State Council in March 2022, to promote the development of the TCM industry, which have brought historical opportunities to the TCM industry. However, TCM industry faces various challenges in the development. In terms of drug development in TCM, the current studies mainly focused on the chemical research and technical requests, which neglected TCM characteristics and cased in conformity between new drug transformation of TCM and clinical practice. Therefore, a more considerable and profound authoritative guideline is needed, and innovative thought and research are necessary for academics and the industry. Through the investigation of the development TCM industry in recent years, this study summarized the policies on and trends of Chinese medicinal materials, new drug development in TCM, catalogue of national basic drugs, and national basic health insurance, and proposed suggestions for further development of TCM industry.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Medicamentos Herbarios Chinos / Medicina Tradicional China Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Humans País/Región como asunto: Asia Idioma: Zh Revista: Zhongguo Zhong Yao Za Zhi Asunto de la revista: FARMACOLOGIA / TERAPIAS COMPLEMENTARES Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Medicamentos Herbarios Chinos / Medicina Tradicional China Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Humans País/Región como asunto: Asia Idioma: Zh Revista: Zhongguo Zhong Yao Za Zhi Asunto de la revista: FARMACOLOGIA / TERAPIAS COMPLEMENTARES Año: 2022 Tipo del documento: Article País de afiliación: China